Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model-Reference-Cited by-同舟云学术

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

Published:2021-01-01 Issue:1 Volume:10 Page:2076-2089
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Lee Ha-Na¹,McWilliams Ian L.¹,Lewkowicz Aaron P.¹,Engel Kaliroi¹,Ireland Derek D. C.¹,Kelley-Baker Logan¹,Thacker Seth¹,Piccardo Pedro²,Manangeeswaran Mohanraj¹,Verthelyi Daniela¹^ORCID

Affiliation:

1. Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

2. Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

Funder

Oak Ridge Institute for Science and Education

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2021.1997075

Reference47 articles.

1. Ebola virus disease and critical illness

2. Cerebrospinal Fluid Examination in Survivors of Ebola Virus Disease